Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy-Reference-Cited by-同舟云学术

Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy

Published:2009-08 Issue:5 Volume:74 Page:1455-1460
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Weiss Christian,von Römer Felix,Capalbo Gianni,Ott Oliver J.,Wittlinger Michael,Krause Steffen F.,Sauer Rolf,Rödel Claus,Rödel Franz

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference40 articles.

1. Optimal management of the T1G3 bladder cancer;Manoharan;Urol Clin North Am,2005

2. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association;Smith;J Urol,1999

3. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder;Amling;J Urol,1994

4. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?;Denzinger;Eur Urol,2008

5. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction;Freeman;Cancer,1995

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer;Minerva Urologica e Nefrologica;2020-06

2. Multimodality Treatment for Bladder Conservation;Urologic Oncology;2019

3. Multimodality Treatment for Bladder Conservation;Urologic Oncology;2017-12-21

4. Molecular effectors of radiation resistance in colorectal cancer;Precision Radiation Oncology;2017-01-11

5. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II α , survivin, and E-cadherin;Human Pathology;2016-11